PCSA (Processa Pharmaceuticals) GF Value : $0.00 (As of Apr. 02, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals GF Value?

As of today (2025-04-02), Processa Pharmaceuticals's share price is $0.412. Processa Pharmaceuticals's GF Value is $0.00. Therefore, Processa Pharmaceuticals's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Processa Pharmaceuticals is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Processa Pharmaceuticals (NAS:PCSA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Processa Pharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.412	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Processa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076

Website

https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Executives

George K Ng	officer: Chief Executive Officer	C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke	director	C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
David Young	director, 10 percent owner, officer: President & CEO	8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin	officer: Chief Business - Strategy Off	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Wendy Guy	officer: Chief Administrative Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker	officer: Chief Financial Officer	9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson	director	319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu	director	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd	officer: Chief Operating Officer	C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora	officer: Chief Development Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076